Current data suggest that a favorable donor selected based on the KIR-HLA genotype for immunotherapy with donor-liver-derived NK cells potentially eliminates the intermediate risk of HCC recurrence after liver transplantation. This evidence concerns the gene KIR3DL1 and hepatocellular carcinoma.